HAMLET B — Hamlet BioPharma AB Cashflow Statement
0.000.00%
- SEK958.40m
- SEK929.85m
Annual cashflow statement for Hamlet BioPharma AB, fiscal year end - June 30th, SEK millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.72 | -17.2 | -20.4 | -41.8 | -54.7 |
| Non-Cash Items | 0.261 | 0.009 | 0.499 | 7.83 | 10.5 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.69 | -3.13 | 0.329 | -2.02 | -38.8 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -5.77 | -20.3 | -19.6 | -36 | -83 |
| Capital Expenditures | — | — | -9.97 | -0.278 | -0.025 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | — | — | -9.97 | -0.278 | -0.025 |
| Financing Cash Flow Items | 0 | -3.66 | -0.132 | -0.779 | -0.277 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0 | 52.5 | 8.37 | 41 | 26.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -5.77 | 32.1 | -21.2 | 4.71 | -12.3 |